282
Participants
Start Date
March 24, 2020
Primary Completion Date
August 1, 2024
Study Completion Date
November 1, 2029
Atezolizumab
The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
RECRUITING
Rigshospitalet, Copenhagen
RECRUITING
Herlev Hospital, Herlev
RECRUITING
Odense Universitetshospital, Odense
RECRUITING
Aarhus University Hospital, Aarhus
RECRUITING
Aalborg Universitetshospital, Aalborg
Aarhus University Hospital
OTHER
Herlev Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Odense University Hospital
OTHER
Aalborg University Hospital
OTHER
Jørgen Bjerggaard Jensen
OTHER